Hypertension in CKD Market Analysis By Drug Class(Diuretics, RAS Blockade, β - Blockers, Calcium Channel Blockers), By Distribution Channel(Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) & Forecast 2023 - 2032

The global hypertension in CKD market size was valued at USD 210 million in 2021 and is projected to reach around USD 450 million in 2030 exhibiting a CAGR of 10.6% in the forecasted period. The growing dominance of dialysis and diuretic therapies in hypertension patients to decrease blood volume in the kidneys is anticipated to boost the growth of the hypertension in CKD market during the forecasted period. Furthermore, a sturdy pipeline of anti-hypertension drugs in the clinical stage to treat CKD in patients with high blood pressure is estimated to add-on growth in the hypertension in CKD market during the estimated period. Conversely, lack of awareness regarding chronic kidney disease (CKD) can be a restraint in the growth of this market.
Rising prevalence of chronic kidney disease (CKD) and diabetic kidney disease (DKD), amongst the age groups is anticipated to drive the market growth over the forecasted period. The growing number of patients undergoing dialysis treatment is anticipated to fuel growth of the global hypertension in CKD market. For example, as per the data issued in the Indian Journal of Public Health (IJPH), in 2018, about 130,000 patients received dialysis treatment in India and the number augmented by nearly 232 patients per million people in India as compared to 2017.
Similarly, as per the Centers for Disease Control and Prevention, (CDC), March 4, 2021, in the U.S., roughly 15% of the U.S. adults or 37 million people are presently suffering from chronic kidney disease. The below graph demonstrates the percentage of U.S. adults in various age groups (18 years and above), suffering from chronic kidney disease:
Moreover, as per the National Institute of Diabetes and Digestive and Kidney Diseases: 2020, high blood glucose can harm the blood vessels in the kidneys, as many people with diabetes also have high blood pressure. This is known as diabetic kidney disease (DKD) in type 2 diabetes. As per the National Center for Biotechnology Information, (NCBI): 2017, the frequency of DKD in most type 2 diabetics, at any point in time, is nearly 30%-50% among the U.S. diabetic adults. This occurrence was ranging among 25% in patients younger than 65 years old to almost 50% with age more than 65 years. Therefore, patients suffering from DKD are at greater chances of suffering from hypertension.
Market companies are indulged in attaining Fast Track Designation for the drugs from the regulatory specialists, which is projected to boost growth of the global hypertension in CKD market over the forecasted period. For example, on March 12, 2020, C.H. Boehringer Sohn AG & Ko. KG and Eli Lilly and Company got the U.S. Food and Drug Administration (FDA) Fast Track designation grant for directing clinical trial of empagliflozin, to check its pharmacokinetics, safety, and efficiency in decreasing the danger of kidney disease progression and cardiovascular demise in adults suffering from chronic kidney disease.
Rising product launches by the market players is anticipated to drive the growth of the global hypertension in CKD market during the prediction period. For example, in 2019, Mankind Pharma introduced anti-hypertensive-drug Zolahart (Azilsartan), which is indicated for 24 hours blood pressure control. It has been found to be efficient in the hypertensive patients with comorbid situations like diabetes and CKD. It fits to the Angiotensin-receptor-blocker class.
The COVID-19 pandemic is anticipated to confine growth of the global hypertension in CKD market over the forecasted period. As per the National Center for Biotechnology Information (NCBI), September 29, 2020, the treatment for chronic kidney diseases might be postponed owing to the pandemic. Furthermore, throughout the COVID-19 pandemic, the handling of kidney disorders patients is suspended or even cancelled owing to the absence of medicines due to uneven supply and transport of drugs.
Furthermore, according to the U.S Food and Drug Administration (FDA), September 18, 2020, the COVID-19 pandemic has disturbed the global drug supply owing to government-mandated or commended temporary shutdowns, safety initiatives to ensure employee health and well-being, insufficient labour force, and limitations on import and export activities, and travel.
Drug Class Insights
On the basis of drug class, the hypertension in CKD market has been categorized into diuretics, RAS blockade, β – blockers, calcium channel blockers, and others. The RAS blockade category is to observe higher adoption of hypertension in CKD during the forecasted period. The major factor boosting the segment is that, it is the first-line choices for decreasing proteinuria and reducing the progression of nephropathy in diabetic patients.
Distribution Channel Insights
On the basis of distribution channel, the hypertension in CKD market has been categorized into retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies category is to observe higher adoption of hypertension in CKD during the forecasted period. This is mostly owing to the accessibility of experienced healthcare professionals & the safety & efficiency throughout the treatment procedures also increasing hospital administration of patients globally are the major aspects for the growth of the segment.
Region Insights
North America characterized a substantial portion of the complete industry as an outcome of the growing commonness of hypertension in end-stage kidney illness, which is projected to boost the global hypertension in CKD market growth over the estimated time duration. As specified by the Centers for Disease Control and Prevention (CDC) calculations in 2019, hypertension was seen in patients aged 65 or above and undergoing constant kidney infection, and as per a similar source, approximately 125,000 individuals in the U.S. initiated treatment for end-stage kidney infection (ESKD) and closely 726,000 (2 in every 1,000 individuals) in 2018 were on dialysis or had gone over kidney relocation.
Moreover, as per the Centers for Disease Control and Prevention, in 2019, nearly 15% women and 12% men were experiencing from CKD in the U.S. Furthermore, in 26% of the cases, hypertension was the main reason for end-stage renal disease incidences.
Key Companies Insights
The market for hypertension in CKD is moderately competitive. With the rising applications of Hypertension in CKD, new players are considering to enter the market. The companies are also involved in events like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the Hypertension in CKD market, ultimately boosting the market growth. Some of the key companies working in the global Hypertension in CKD market include:
• Novartis International AG
• AstraZeneca Plc
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A
• KBP Biosciences Holdings Limited
• Ardelyx
• Reata Pharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• C.H. Boehringer Sohn AG & Ko. KG.
• Other players
Some of the Recent Developments:
• In February 2021, AstraZeneca Plc received permission from Drugs Controller General of India (DCGI) for Dapagliflozin tablets for the management of patients suffering from hypertension in chronic kidney disease.
• In June 2020, Ardelyx submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the sanction of tenapanor for the treatment of hyperphosphatemia in the U.S.
Segments
By Drug Class
• Diuretics
• RAS Blockade
• β - Blockers
• Calcium Channel Blockers
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies
By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt